In T1D, where exogenous insulin is required, protein’s glucagon-stimulating properties can be leveraged to prevent delayed or overnight hypoglycemia, assist during prolonged activity, or enhance mild hypoglycemia treatment (22, 31, 34). This evidence concerns the gene INS and Hypoglycemia.